Drugs / CD19/CD22-CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06213636 | Jul 2024 → Feb 2027 expected | B-cell adult acute lymphocytic leukemia, central nervous system non-hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22-CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06213636 ↗ |
| Action | Deplete | “This binding triggers a cytotoxic response, resulting in the destruction of the target B cells.” NCT06213636 ↗ |
| Modality | Cell therapy | “This clinical trial involves the use of Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting CD19 and CD22” NCT06213636 ↗ |
| Route | Intravenous | “CD19/CD22-CAR T cells intravenously (IV)” NCT06213636 ↗ |
| Target | CD19 | “targeting CD19 and CD22” NCT06213636 ↗ |
| Target | CD22 | “targeting CD19 and CD22” NCT06213636 ↗ |